M. Ogawa

Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly

T. Heineman, M. Shiramoto, M. Eda, 2016, Human vaccines & immunotherapeutics.

The first reported case of Japanese spotted fever in Hiroshima Prefecture, Japan.

Y. Shimazu, S. Fukuda, S. Takao, 2000, Japanese journal of infectious diseases.

Efficacy, Safety and Immunogenicity of a Novel Adjuvanted Subunit Herpes Zoster Vaccine in Japanese Aged 50 Years and 70 Years and Older

H. Ikematsu, Martina Kovac, D. Watanabe, 2018 .